NCT05121714View on ClinicalTrials.gov

Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

May 18, 2021

Study Completion Date

May 18, 2021

Conditions
Healthy
Interventions
DRUG

Caffeine

This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)

DRUG

ABX464

This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine) and a known CYP1A2 substrate (caffeine).

DRUG

Fluvoxamine

his is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 inhibitor (fluvoxamine).

Trial Locations (1)

CF48 4DR

Simbec-Orion, Merthyr Tydfil

Sponsors

Lead Sponsor

Abivax S.A.
All Listed Sponsors
lead

Abivax S.A.

INDUSTRY